DNA replication and cancer: From dysfunctional replication origin activities to therapeutic opportunities

Seminars in Cancer Biology

Volumn 37-38, Issue , 2016, Pages 16-25

  Boyer, Anne Sophie ^a   Walter, David ^a   Sørensen, Claus Storgaard ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cancer therapy; Fork restart; Genetic instability; Oncogenes; Replicative stress

Indexed keywords

ATR PROTEIN; CELL CYCLE PROTEIN 6; CHECKPOINT KINASE 1; CYCLIN DEPENDENT KINASE 6; MINICHROMOSOME MAINTENANCE PROTEIN 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN P53; RAD51 PROTEIN;

ACUTE MYELOBLASTIC LEUKEMIA; ANAPHASE; CANCER CELL; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL COUNT; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; DNA ALKYLATION; DNA CLEAVAGE; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; DNA SEQUENCE; DNA STRAND BREAKAGE; DNA STRUCTURE; DNA SYNTHESIS; DNA TEMPLATE; GENE MUTATION; GENOMIC INSTABILITY; HUMAN; MITOSIS; NONHUMAN; ONCOGENE; OVARY CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REVIEW; SKIN CANCER; DNA REPLICATION ORIGIN; GENETICS; NEOPLASM; PERSONALIZED MEDICINE; PROCEDURES;

DNA DAMAGE; DNA REPLICATION; GENOMIC INSTABILITY; HUMANS; NEOPLASMS; ONCOGENES; PRECISION MEDICINE; REPLICATION ORIGIN;

EID: 84955474177     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2016.01.001     Document Type: Review

References (160)

1. Zeman M.K., Cimprich K.A. Causes and consequences of replication stress. Nat. Cell Biol. 2014, 16:2-9.
2. Magdalou I., Lopez B.S., Pasero P., Lambert S.A. The causes of replication stress and their consequences on genome stability and cell fate. Semin. Cell Dev. Biol. 2014, 30:154-164.
3. Bartkova J., Horejsi Z., Koed K., Kramer A., Tort F., Zieger K., et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005, 434:864-870.
4. Macheret M., Halazonetis T.D. DNA replication stress as a hallmark of cancer. Annu. Rev. Pathol. 2015, 10:425-448.
5. Gaillard H., Garcia-Muse T., Aguilera A. Replication stress and cancer. Nat. Rev. Cancer 2015, 15:276-289.
6. Hills S.A., Diffley J.F. DNA replication and oncogene-induced replicative stress. Curr. Biol. 2014, 24:R435-44.
7. Bartek J., Bartkova J., Lukas J. DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene 2007, 26:7773-7779.
8. Lemee F., Bergoglio V., Fernandez-Vidal A., Machado-Silva A., Pillaire M.J., Bieth A., et al. DNA polymerase theta up-regulation is associated with poor survival in breast cancer, perturbs DNA replication, and promotes genetic instability. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:13390-13395.
9. Higgins G.S., Harris A.L., Prevo R., Helleday T., McKenna W.G., Buffa F.M. Overexpression of POLQ confers a poor prognosis in early breast cancer patients. Oncotarget 2010, 1:175-184.
10. Dobbelstein M., Sorensen C.S. Exploiting replicative stress to treat cancer. Nat. Rev. Drug Discov. 2015, 14:405-423.
11. Debatisse M., Le Tallec B., Letessier A., Dutrillaux B., Brison O. Common fragile sites: mechanisms of instability revisited. Trends Genet. 2012, 28:22-32.
12. Remus D., Beuron F., Tolun G., Griffith J.D., Morris E.P., Diffley J.F. Concerted loading of Mcm2-7 double hexamers around DNA during DNA replication origin licensing. Cell 2009, 139:719-730.
13. Gambus A., Khoudoli G.A., Jones R.C., Blow J.J. MCM2-7 form double hexamers at licensed origins in Xenopus egg extract. J. Biol. Chem. 2011, 286:11855-11864.
14. Evrin C., Clarke P., Zech J., Lurz R., Sun J., Uhle S., et al. A double-hexameric MCM2-7 complex is loaded onto origin DNA during licensing of eukaryotic DNA replication. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:20240-20245.
15. Moyer S.E., Lewis P.W., Botchan M.R. Isolation of the Cdc45/Mcm2-7/GINS (CMG) complex, a candidate for the eukaryotic DNA replication fork helicase. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:10236-10241.
16. Ilves I., Petojevic T., Pesavento J.J., Botchan M.R. Activation of the MCM2-7 helicase by association with Cdc45 and GINS proteins. Mol. Cell 2010, 37:247-258.
17. Gambus A., Jones R.C., Sanchez-Diaz A., Kanemaki M., van Deursen F., Edmondson R.D., et al. GINS maintains association of Cdc45 with MCM in replisome progression complexes at eukaryotic DNA replication forks. Nat. Cell Biol. 2006, 8:358-366.
18. Shirayama M., Toth A., Galova M., Nasmyth K. APC(Cdc20) promotes exit from mitosis by destroying the anaphase inhibitor Pds1 and cyclin Clb5. Nature 1999, 402:203-207.
19. Rhind N., Gilbert D.M. DNA replication timing. Cold Spring Harb. Perspect. Med. 2013, 3:1-26.
20. Wong P.G., Winter S.L., Zaika E., Cao T.V., Oguz U., Koomen J.M., et al. Cdc45 limits replicon usage from a low density of preRCs in mammalian cells. PLoS One 2011, 6:e17533.
21. Takahashi T.S., Wigley D.B., Walter J.C. Pumps, paradoxes and ploughshares: mechanism of the MCM2-7 DNA helicase. Trends Biochem. Sci. 2005, 30:437-444.
22. Hyrien O., Marheineke K., Goldar A. Paradoxes of eukaryotic DNA replication: MCM proteins and the random completion problem BioEssays: news and reviews in molecular. Cell. Dev. Biol. 2003, 25:116-125.
23. Woodward A.M., Gohler T., Luciani M.G., Oehlmann M., Ge X., Gartner A., et al. Excess Mcm2-7 license dormant origins of replication that can be used under conditions of replicative stress. J. Cell Biol. 2006, 173:673-683.
24. Blow J.J., Ge X.Q., Jackson D.A. How dormant origins promote complete genome replication. Trends Biochem. Sci. 2011, 36:405-414.
25. Ge X.Q., Blow J.J. Chk1 inhibits replication factory activation but allows dormant origin firing in existing factories. J. Cell Biol. 2010, 191:1285-1297.
26. Cortez D., Glick G., Elledge S.J. Minichromosome maintenance proteins are direct targets of the ATM and ATR checkpoint kinases. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:10078-10083.
27. Chen Y.H., Jones M.J., Yin Y., Crist S.B., Colnaghi L., Sims R.J., et al. ATR-mediated phosphorylation of FANCI regulates dormant origin firing in response to replication stress. Mol. Cell 2015, 58:323-338.
28. Shreeram S., Sparks A., Lane D.P., Blow J.J. Cell type-specific responses of human cells to inhibition of replication licensing. Oncogene 2002, 21:6624-6632.
29. Blow J.J., Gillespie P.J. Replication licensing and cancer-a fatal entanglement. Nat. Rev. Cancer 2008, 8:799-806.
30. Nevis K.R., Cordeiro-Stone M., Cook J.G. Origin licensing and p53 status regulate Cdk2 activity during G(1). Cell Cycle 2009, 8:1952-1963.
31. Machida Y.J., Teer J.K., Dutta A. Acute reduction of an origin recognition complex (ORC) subunit in human cells reveals a requirement of ORC for Cdk2 activation. J. Biol. Chem. 2005, 280:27624-27630.
32. Feng D., Tu Z., Wu W., Liang C. Inhibiting the expression of DNA replication-initiation proteins induces apoptosis in human cancer cells. Cancer Res. 2003, 63:7356-7364.
33. Liu P., Slater D.M., Lenburg M., Nevis K., Cook J.G., Vaziri C. Replication licensing promotes cyclin D1 expression and G1 progression in untransformed human cells. Cell Cycle 2009, 8:125-136.
34. Bicknell L.S., Walker S., Klingseisen A., Stiff T., Leitch A., Kerzendorfer C., et al. Mutations in ORC1, encoding the largest subunit of the origin recognition complex, cause microcephalic primordial dwarfism resembling Meier-Gorlin syndrome. Nat. Genet. 2011, 43:350-355.
35. Klingseisen A., Jackson A.P. Mechanisms and pathways of growth failure in primordial dwarfism. Genes Dev. 2011, 25:2011-2024.
36. de Munnik S.A., Bicknell L.S., Aftimos S., Al-Aama J.Y., van Bever Y., Bober M.B., et al. Meier-Gorlin syndrome genotype-phenotype studies: 35 individuals with pre-replication complex gene mutations and 10 without molecular diagnosis. Eur. J. Hum. Genet. 2012, 20:598-606.
37. Kuo A.J., Song J., Cheung P., Ishibe-Murakami S., Yamazoe S., Chen J.K., et al. The BAH domain of ORC1 links H4K20me2 to DNA replication licensing and Meier-Gorlin syndrome. Nature 2012, 484:115-119.
38. Ibarra A., Schwob E., Mendez J. Excess MCM proteins protect human cells from replicative stress by licensing backup origins of replication. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:8956-8961.
39. Ge X.Q., Jackson D.A., Blow J.J. Dormant origins licensed by excess Mcm2-7 are required for human cells to survive replicative stress. Genes Dev. 2007, 21:3331-3341.
40. Kawabata T., Luebben S.W., Yamaguchi S., Ilves I., Matise I., Buske T., et al. Stalled fork rescue via dormant replication origins in unchallenged S phase promotes proper chromosome segregation and tumor suppression. Mol. Cell 2011, 41:543-553.
41. Burrell R.A., McClelland S.E., Endesfelder D., Groth P., Weller M.C., Shaikh N., et al. Replication stress links structural and numerical cancer chromosomal instability. Nature 2013, 494:492-496.
42. Hwang H.C., Clurman B.E., Cyclin E. in normal and neoplastic cell cycles. Oncogene 2005, 24:2776-2786.
43. Ekholm-Reed S., Mendez J., Tedesco D., Zetterberg A., Stillman B., Reed S.I. Deregulation of cyclin E in human cells interferes with prereplication complex assembly. J. Cell Biol. 2004, 165:789-800.
44. Dominguez-Sola D., Ying C.Y., Grandori C., Ruggiero L., Chen B., Li M., et al. Non-transcriptional control of DNA replication by c-Myc. Nature 2007, 448:445-451.
45. Srinivasan S.V., Dominguez-Sola D., Wang L.C., Hyrien O., Gautier J. Cdc45 is a critical effector of myc-dependent DNA replication stress. Cell Rep. 2013, 3:1629-1639.
46. Toledo L.I., Altmeyer M., Rask M.B., Lukas C., Larsen D.H., Povlsen L.K., et al. ATR prohibits replication catastrophe by preventing global exhaustion of RPA. Cell 2013, 155:1088-1103.
47. Bester A.C., Roniger M., Oren Y.S., Im M.M., Sarni D., Chaoat M., et al. Nucleotide deficiency promotes genomic instability in early stages of cancer development. Cell 2011, 145:435-446.
48. Di Micco R., Fumagalli M., Cicalese A., Piccinin S., Gasparini P., Luise C., et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006, 444:638-642.
49. Jones R.M., Mortusewicz O., Afzal I., Lorvellec M., Garcia P., Helleday T., et al. Increased replication initiation and conflicts with transcription underlie Cyclin E-induced replication stress. Oncogene 2013, 32:3744-3753.
50. Beck H., Nahse-Kumpf V., Larsen M.S., O'Hanlon K.A., Patzke S., Holmberg C., et al. Cyclin-dependent kinase suppression by WEE1 kinase protects the genome through control of replication initiation and nucleotide consumption. Mol. Cell. Biol. 2012, 32:4226-4236.
51. Pfister S.X., Markkanen E., Jiang Y., Sarkar S., Woodcock M., Orlando G., et al. Inhibiting WEE1 selectively kills histone H3K36me3-deficient cancers by dNTP starvation. Cancer Cell 2015, 5:557-568.
52. Gonzalez M.A., Tachibana K.E., Laskey R.A., Coleman N. Control of DNA replication and its potential clinical exploitation. Nat. Rev. Cancer 2005, 5:135-141.
53. Vaziri C., Saxena S., Jeon Y., Lee C., Murata K., Machida Y., et al. A p53-dependent checkpoint pathway prevents rereplication. Mol. Cell 2003, 11:997-1008.
54. Liontos M., Koutsami M., Sideridou M., Evangelou K., Kletsas D., Levy B., et al. Deregulated overexpression of hCdt1 and hCdc6 promotes malignant behavior. Cancer Res. 2007, 67:10899-10909.
55. Seo J., Chung Y.S., Sharma G.G., Moon E., Burack W.R., Pandita T.K., et al. Cdt1 transgenic mice develop lymphoblastic lymphoma in the absence of p53. Oncogene 2005, 24:8176-8186.
56. Petersen B.O., Lukas J., Sorensen C.S., Bartek J., Helin K. Phosphorylation of mammalian CDC6 by cyclin A/CDK2 regulates its subcellular localization. EMBO J. 1999, 18:396-410.
57. Saha T., Ghosh S., Vassilev A., DePamphilis M.L. Ubiquitylation, phosphorylation and Orc2 modulate the subcellular location of Orc1 and prevent it from inducing apoptosis. J. Cell Sci. 2006, 119:1371-1382.
58. Tatsumi Y., Sugimoto N., Yugawa T., Narisawa-Saito M., Kiyono T., Fujita M. Deregulation of Cdt1 induces chromosomal damage without rereplication and leads to chromosomal instability. J. Cell Sci. 2006, 119:3128-3140.
59. Arias E.E., Walter J.C. Replication-dependent destruction of Cdt1 limits DNA replication to a single round per cell cycle in Xenopus egg extracts. Genes Dev. 2005, 19:114-126.
60. Melixetian M., Ballabeni A., Masiero L., Gasparini P., Zamponi R., Bartek J., et al. Loss of Geminin induces rereplication in the presence of functional p53. J. Cell Biol. 2004, 165:473-482.
61. Petersen B.O., Wagener C., Marinoni F., Kramer E.R., Melixetian M., Lazzerini Denchi E., et al. Cell cycle- and cell growth-regulated proteolysis of mammalian CDC6 is dependent on APC-CDH1. Genes Dev. 2000, 14:2330-2343.
62. Mailand N., Diffley J.F. CDKs promote DNA replication origin licensing in human cells by protecting Cdc6 from APC/C-dependent proteolysis. Cell 2005, 122:915-926.
63. Duursma A., Agami R. p53-Dependent regulation of Cdc6 protein stability controls cellular proliferation. Mole. Cell. Biol. 2005, 25:6937-6947.
64. Hall J.R., Kow E., Nevis K.R., Lu C.K., Luce K.S., Zhong Q., et al. Cdc6 stability is regulated by the Huwe1 ubiquitin ligase after DNA damage. Mol. Biol. Cell. 2007, 18:3340-3350.
65. Gonzalez S., Klatt P., Delgado S., Conde E., Lopez-Rios F., Sanchez-Cespedes M., et al. Oncogenic activity of Cdc6 through repression of the INK4/ARF locus. Nature 2006, 440:702-706.
66. Sideridou M., Zakopoulou R., Evangelou K., Liontos M., Kotsinas A., Rampakakis E., et al. Cdc6 expression represses E-cadherin transcription and activates adjacent replication origins. J. Cell Biol. 2011, 195:1123-1140.
67. O'Driscoll M., Jeggo P.A. The role of the DNA damage response pathways in brain development and microcephaly: insight from human disorders. DNA Repair 2008, 7:1039-1050.
68. Ogi T., Walker S., Stiff T., Hobson E., Limsirichaikul S., Carpenter G., et al. Identification of the first ATRIP-deficient patient and novel mutations in ATR define a clinical spectrum for ATR-ATRIP Seckel Syndrome. PLoS Genet. 2012, 8:e1002945.
69. Murga M., Bunting S., Montana M.F., Soria R., Mulero F., Canamero M., et al. A mouse model of ATR-Seckel shows embryonic replicative stress and accelerated aging. Nat. Genet. 2009, 41:891-898.
70. Lecona E., Fernandez-Capetillo O. Replication stress and cancer: it takes two to tango. Exp. Cell Res. 2014, 329:26-34.
71. Ghosal G., Chen J. DNA damage tolerance: a double-edged sword guarding the genome. Transl. Cancer Res. 2013, 2:107-129.
72. Marechal A., Zou L. DNA damage sensing by the ATM and ATR kinases. Cold Spring Harb. Perspect. Biol. 2013, 2013.
73. Friedberg E.C. Suffering in silence: the tolerance of DNA damage. Nat. Rev. Mol. Cell Biol. 2005, 6:943-953.
74. Hoffmann J.S., Cazaux C. Aberrant expression of alternative DNA polymerases: a source of mutator phenotype as well as replicative stress in cancer. Semin. Cancer Biol. 2010, 20:312-319.
75. Pan Q., Fang Y., Xu Y., Zhang K., Hu X. Down-regulation of DNA polymerases kappa, eta, iota, and zeta in human lung, stomach, and colorectal cancers. Cancer Lett. 2005, 217:139-147.
76. Masutani C., Kusumoto R., Yamada A., Dohmae N., Yokoi M., Yuasa M., et al. The XPV (xeroderma pigmentosum variant) gene encodes human DNA polymerase eta. Nature. 1999, 399:700-704.
77. Johnson R.E., Prakash S., Prakash L. Efficient bypass of a thymine-thymine dimer by yeast DNA polymerase, Poleta. Science 1999, 283:1001-1004.
78. Boyer A.S., Grgurevic S., Cazaux C., Hoffmann J.S. The human specialized DNA polymerases and non-B DNA: vital relationships to preserve genome integrity. J. Mol. Biol. 2013, 425:4767-4781.
79. Baptiste B.A., Eckert K.A. DNA polymerase kappa microsatellite synthesis: two distinct mechanisms of slippage-mediated errors. Environ. MolM Mutagen. 2012, 53:787-796.
80. Mukherjee P., Lahiri I., Pata J.D. Human polymerase kappa uses a template-slippage deletion mechanism, but can realign the slipped strands to favour base substitution mutations over deletions. Nucleic Acids Res. 2013, 41:5024-5035.
81. Leon-Ortiz A.M., Svendsen J., Boulton S.J. Metabolism of DNA secondary structures at the eukaryotic replication fork. DNA Repair 2014, 19:152-162.
82. Fry M., Loeb L.A. Human werner syndrome DNA helicase unwinds tetrahelical structures of the fragile X syndrome repeat sequence d(CGG)n. J. Biol. Chem. 1999, 274:12797-12802.
83. Sun H., Karow J.K., Hickson I.D., Maizels N. The Bloom's syndrome helicase unwinds G4 DNA. J. Biol. Chem. 1998, 273:27587-27592.
84. Singh D.K., Ghosh A.K., Croteau D.L., Bohr V.A. RecQ helicases in DNA double strand break repair and telomere maintenance. Mutat. Res. 2012, 736:15-24.
85. Wu Y., Shin-ya K., Brosh R.M. FANCJ helicase defective in Fanconia anemia and breast cancer unwinds G-quadruplex DNA to defend genomic stability. Mol. Cell. Biol. 2008, 28:4116-4128.
86. Cantor S.B., Guillemette S. Hereditary breast cancer and the BRCA1-associated FANCJ/BACH1/BRIP1. Future Oncol. 2011, 7:253-261.
87. Sanders C.M. Human Pif1 helicase is a G-quadruplex DNA-binding protein with G-quadruplex DNA-unwinding activity. Biochem. J. 2016, 430:119-128.
88. Vannier J.B., Pavicic-Kaltenbrunner V., Petalcorin M.I., Ding H., Boulton S.J. RTEL1 dismantles T loops and counteracts telomeric G4-DNA to maintain telomere integrity. Cell 2012, 149:795-806.
89. Vannier J.B., Sarek G., Boulton S.J. RTEL1: functions of a disease-associated helicase. Trends Cell Biol. 2014, 24:416-425.
90. Kamath-Loeb A.S., Loeb L.A., Johansson E., Burgers P.M., Fry M. Interactions between the Werner syndrome helicase and DNA polymerase delta specifically facilitate copying of tetraplex and hairpin structures of the d(CGG)n trinucleotide repeat sequence. J. Biol. Chem. 2001, 276:16439-16446.
91. Sarkies P., Murat P., Phillips L.G., Patel K.J., Balasubramanian S., Sale J.E. FANCJ coordinates two pathways that maintain epigenetic stability at G-quadruplex DNA. Nucleic Acids Res. 2012, 40:1485-1498.
92. Sarkies P., Reams C., Simpson L.J., Sale J.E. Epigenetic instability due to defective replication of structured DNA. Mol. Cell 2010, 40:703-713.
93. Heller R.C., Marians K.J. Replication fork reactivation downstream of a blocked nascent leading strand. Nature 2006, 439:557-562.
94. Daigaku Y., Davies A.A., Ulrich H.D. Ubiquitin-dependent DNA damage bypass is separable from genome replication. Nature 2010, 465:951-955.
95. Karras G.I., Jentsch S. The RAD6 DNA damage tolerance pathway operates uncoupled from the replication fork and is functional beyond S phase. Cell 2010, 141:255-267.
96. Mouron S., Rodriguez-Acebes S., Martinez-Jimenez M.I., Garcia-Gomez S., Chocron S., Blanco L., et al. Repriming of DNA synthesis at stalled replication forks by human PrimPol. Nat. Struct. Mol. Biol. 2013, 20:1383-1389.
97. Bianchi J., Rudd S.G., Jozwiakowski S.K., Bailey L.J., Soura V., Taylor E., et al. PrimPol bypasses UV photoproducts during eukaryotic chromosomal DNA replication. Mol. Cell 2013, 52:566-573.
98. Garcia-Gomez S., Reyes A., Martinez-Jimenez M.I., Chocron E.S., Mouron S., Terrados G., et al. PrimPol, an archaic primase/polymerase operating in human cells. Mol. Cell 2013, 52:541-553.
99. Keen B.A., Bailey L.J., Jozwiakowski S.K., Doherty A.J. Human PrimPol mutation associated with high myopia has a DNA replication defect. Nucleic Acids Res. 2014, 42:12102-12111.
100. Higgins N.P., Kato K., Strauss B. A model for replication repair in mammalian cells. J. Mol. Biol. 1976, 101:417-425.
101. Sogo J.M., Lopes M., Foiani M. Fork reversal and ssDNA accumulation at stalled replication forks owing to checkpoint defects. Science 2002, 297:599-602.
102. Saugar I., Ortiz-Bazan M.A., Tercero J.A. Tolerating DNA damage during eukaryotic chromosome replication. Exp. Cell Res. 2014, 329:170-177.
103. Branzei D., Foiani M. Maintaining genome stability at the replication fork. Nat. Rev. Mol. Cell Biol. 2010, 11:208-219.
104. Atkinson J., McGlynn P. Replication fork reversal and the maintenance of genome stability. Nucleic Acids Res. 2009, 37:3475-3492.
105. Follonier C., Oehler J., Herrador R., Lopes M. Friedreich's ataxia-associated GAA repeats induce replication-fork reversal and unusual molecular junctions. Nat. Struct. Mol. Biol. 2013, 20:486-494.
106. McMurray C.T. Mechanisms of trinucleotide repeat instability during human development. Nat. Rev. Genet. 2010, 11:786-799.
107. Mirkin S.M. Expandable DNA repeats and human disease. Nature 2007, 447:932-940.
108. Zellweger R., Dalcher D., Mutreja K., Berti M., Schmid J.A., Herrador R., et al. Rad51-mediated replication fork reversal is a global response to genotoxic treatments in human cells. J. Cell Biol. 2015, 208:563-579.
109. Hashimoto Y., Ray Chaudhuri A., Lopes M., Costanzo V. Rad51 protects nascent DNA from Mre11-dependent degradation and promotes continuous DNA synthesis. Nat. Struct. Mol. Biol. 2010, 17:1305-1311.
110. Alabert C., Bukowski-Wills J.C., Lee S.B., Kustatscher G., Nakamura K., de Lima Alves F., et al. Nascent chromatin capture proteomics determines chromatin dynamics during DNA replication and identifies unknown fork components. Nat. Cell Biol. 2014, 16:281-293.
111. Petermann E., Orta M.L., Issaeva N., Schultz N., Helleday T. Hydroxyurea-stalled replication forks become progressively inactivated and require two different RAD51-mediated pathways for restart and repair. Mol. Cell 2010, 37:492-502.
112. Fugger K., Mistrik M., Danielsen J.R., Dinant C., Falck J., Bartek J., et al. Human Fbh1 helicase contributes to genome maintenance via pro- and anti-recombinase activities. J. Cell Biol. 2009, 186:655-663.
113. Fugger K., Mistrik M., Neelsen K.J., Yao Q., Zellweger R., Kousholt A.N., et al. FBH1catalyzes regression of stalled replication forks. Cell Rep. 2015.
114. Baradaran-Heravi A., Cho K.S., Tolhuis B., Sanyal M., Morozova O., Morimoto M., et al. Penetrance of biallelic SMARCAL1 mutations is associated with environmental and genetic disturbances of gene expression. Hum. Mol. Genet. 2012, 21:2572-2587.
115. Betous R., Couch F.B., Mason A.C., Eichman B.F., Manosas M., Cortez D. Substrate-selective repair and restart of replication forks by DNA translocases. Cell Rep. 2013, 3:1958-1969.
116. Machwe A., Xiao L., Groden J., Orren D.K. The Werner and Bloom syndrome proteins catalyze regression of a model replication fork. Biochemistry 2006, 45:13939-13946.
117. Kanagaraj R., Saydam N., Garcia P.L., Zheng L., Janscak P. Human RECQ5beta helicase promotes strand exchange on synthetic DNA structures resembling a stalled replication fork. Nucleic Acids Res. 2006, 34:5217-5231.
118. Bugreev D.V., Rossi M.J., Mazin A.V. Cooperation of RAD51 and RAD54 in regression of a model replication fork. Nucleic Acids Res. 2011, 39:2153-2164.
119. Gari K., Decaillet C., Delannoy M., Wu L., Constantinou A. Remodeling of DNA replication structures by the branch point translocase FANCM. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:16107-16112.
120. Gari K., Decaillet C., Stasiak A.Z., Stasiak A., Constantinou A. The Fanconi anemia protein FANCM can promote branch migration of Holliday junctions and replication forks. Mol. Cell 2008, 29:141-148.
121. Blastyak A., Hajdu I., Unk I., Haracska L. Role of double-stranded DNA translocase activity of human HLTF in replication of damaged DNA. Mol. Cell. Biol. 2010, 30:684-693.
122. Yuan J., Ghosal G., Chen J. The HARP-like domain-containing protein AH2/ZRANB3 binds to PCNA and participates in cellular response to replication stress. Mol. Cell 2012, 47:410-421.
123. Ciccia A., Nimonkar A.V., Hu Y., Hajdu I., Achar Y.J., Izhar L., et al. Polyubiquitinated PCNA recruits the ZRANB3 translocase to maintain genomic integrity after replication stress. Mol. Cell. 2012, 47:396-409.
124. Ray Chaudhuri A., Hashimoto Y., Herrador R., Neelsen K.J., Fachinetti D., Bermejo R., et al. Topoisomerase I poisoning results in PARP-mediated replication fork reversal. Nat. Struct. Mol. Biol. 2012, 19:417-423.
125. Neelsen K.J., Zanini I.M., Herrador R., Lopes M. Oncogenes induce genotoxic stress by mitotic processing of unusual replication intermediates. J. Cell Biol. 2013, 200:699-708.
126. Thangavel S., Berti M., Levikova M., Pinto C., Gomathinayagam S., Vujanovic M., et al. DNA2 drives processing and restart of reversed replication forks in human cells. J. Cell Biol. 2015, 208:545-562.
127. Schlacher K., Wu H., Jasin M. A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1/2. Cancer Cell 2012, 22:106-116.
128. Schlacher K., Christ N., Siaud N., Egashira A., Wu H., Jasin M. Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11. Cell 2011, 145:529-542.
129. Berti M., Ray Chaudhuri A., Thangavel S., Gomathinayagam S., Kenig S., Vujanovic M., et al. Human RECQ1 promotes restart of replication forks reversed by DNA topoisomerase I inhibition. Nat. Struct. Mol. Biol. 2013, 20:347-354.
130. Cybulski C., Carrot-Zhang J., Kluzniak W., Rivera B., Kashyap A., Wokolorczyk D., et al. Germline RECQL mutations are associated with breast cancer susceptibility. Nat. Genet. 2015, 47:643-646.
131. Brosh R.M. DNA helicases involved in DNA repair and their roles in cancer. Nat. Rev. Cancer 2013, 13:542-558.
132. Fugger K., Chu W.K., Haahr P., Kousholt A.N., Beck H., Payne M.J., et al. FBH1 co-operates with MUS81 in inducing DNA double-strand breaks and cell death following replication stress. Nat. Commun. 2013, 4:1423.
133. Couch F.B., Bansbach C.E., Driscoll R., Luzwick J.W., Glick G.G., Betous R., et al. ATR phosphorylates SMARCAL1 to prevent replication fork collapse. Genes Dev. 2013, 27:1610-1623.
134. Gelot C., Magdalou I., Lopez B.S. Replication stress in Mammalian cells and its consequences for mitosis. Genes 2015, 6:267-298.
135. Negrini S., Gorgoulis V.G., Halazonetis T.D. Genomic instability-an evolving hallmark of cancer. Nat. Rev. Mol. Cell Biol. 2010, 11:220-228.
136. Kennedy R.D., Chen C.C., Stuckert P., Archila E.M., De la Vega M.A., Moreau L.A., et al. Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. J. Clin. Investig. 2007, 117:1440-1449.
137. Chen Z., Xiao Z., Gu W.Z., Xue J., Bui M.H., Kovar P., et al. Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics. Int. J. Cancer 2006, 119:2784-2794.
138. Henry-Mowatt J., Jackson D., Masson J.Y., Johnson P.A., Clements P.M., Benson F.E., et al. XRCC3 and Rad51 modulate replication fork progression on damaged vertebrate chromosomes. Mol. Cell 2003, 11:1109-1117.
139. Ikegami S., Taguchi T., Ohashi M., Oguro M., Nagano H., Mano Y. Aphidicolin prevents mitotic cell division by interfering with the activity of DNA polymerase-alpha. Nature 1978, 275:458-460.
140. Saintigny Y., Delacote F., Vares G., Petitot F., Lambert S., Averbeck D., et al. Characterization of homologous recombination induced by replication inhibition in mammalian cells. EMBO J. 2001, 20:3861-3870.
141. Lundin C., Erixon K., Arnaudeau C., Schultz N., Jenssen D., Meuth M., et al. Different roles for nonhomologous end joining and homologous recombination following replication arrest in mammalian cells. Mol. Cell. Biol. 2002, 22:5869-5878.
142. Pommier Y. Drugging topoisomerases: lessons and challenges. ACS Chem. Biol. 2013, 8:82-95.
143. Regairaz M., Zhang Y.W., Fu H., Agama K.K., Tata N., Agrawal S., et al. Mus81-mediated DNA cleavage resolves replication forks stalled by topoisomerase I-DNA complexes. J. Cell Biol. 2011, 195:739-749.
144. Sorensen C.S., Syljuasen R.G. Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication. Nucleic Acids Res. 2012, 40:477-486.
145. Syljuasen R.G., Sorensen C.S., Hansen L.T., Fugger K., Lundin C., Johansson F., et al. Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol. Cell. Biol. 2005, 25:3553-3562.
146. Zhou B.B., Bartek J. Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat. Rev. Cancer 2004, 4:216-225.
147. Toledo L.I., Murga M., Fernandez-Capetillo O. Targeting ATR and Chk1 kinases for cancer treatment: a new model for new (and old) drugs. Mol. Oncol. 2011, 5:368-373.
148. Petermann E., Woodcock M., Helleday T. Chk1 promotes replication fork progression by controlling replication initiation. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:16090-16095.
149. Bouwman P., Jonkers J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat. Rev. Cancer. 2012, 12:587-598.
150. Bryant H.E., Schultz N., Thomas H.D., Parker K.M., Flower D., Lopez E., et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913-917.
151. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
152. Kim G., Ison G., McKee A.E., Zhang H., Tang S., Gwise T., et al. FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2015, 21:4257-4261.
153. Jiang H., Reinhardt H.C., Bartkova J., Tommiska J., Blomqvist C., Nevanlinna H., et al. The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev. 2009, 23:1895-1909.
154. Velimezi G., Liontos M., Vougas K., Roumeliotis T., Bartkova J., Sideridou M., et al. Functional interplay between the DNA-damage-response kinase ATM and ARF tumour suppressor protein in human cancer. Nat. Cell Biol. 2013, 15:967-977.
155. Soucy T.A., Dick L.R., Smith P.G., Milhollen M.A., Brownell J.E. The NEDD8 conjugation pathway and its relevance in cancer biology and therapy. Genes Cancer 2010, 1:708-716.
156. Nawrocki S.T., Kelly K.R., Smith P.G., Espitia C.M., Possemato A., Beausoleil S.A., et al. Disrupting protein NEDDylation with MLN4924 is a novel strategy to target cisplatin resistance in ovarian cancer. Clin. Cancer Res. 2013, 19:3577-3590.
157. Toth J.I., Yang L., Dahl R., Petroski M.D. A gatekeeper residue for NEDD8-activating enzyme inhibition by MLN4924. Cell Rep. 2012, 1:309-316.
158. Tanaka T., Nakatani T., Kamitani T. Negative regulation of NEDD8 conjugation pathway by novel molecules and agents for anticancer therapy. Curr. Pharm. Design 2013, 19:4131-4139.
159. Nawrocki S.T., Kelly K.R., Smith P.G., Keaton M., Carraway H., Sekeres M.A., et al. The NEDD8-activating enzyme inhibitor MLN4924 disrupts nucleotide metabolism and augments the efficacy of cytarabine. Clin. Cancer Res. 2015, 21:439-447.
160. Lin J.J., Milhollen M.A., Smith P.G., Narayanan U., Dutta A. NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. Cancer Res. 2010, 70:10310-10320.